Drug Repositioning Research Utilizing a Large-scale Medical Claims Database to Improve Survival Rates after Cardiopulmonary Arrest
Approximately 100000 people suffer cardiopulmonary arrest in Japan every year, and the aging of society means that this number is expected to increase. Worldwide, approximately 100 million develop cardiac arrest annually, making it an international issue. Although survival has improved thanks to advances in cardiopulmonary resuscitation, there is a high rate of postresuscitation encephalopathy after the return of spontaneous circulation, and the proportion of patients who can return to normal life is extremely low. Treatment for postresuscitation encephalopathy is long term, and if sequelae persist then nursing care is required, causing immeasurable economic burdens as a result of ballooning medical costs. As at present there is no drug treatment to improve postresuscitation encephalopathy as a complication of cardiopulmonary arrest, the development of novel drug treatments is desirable. In recent years, new efficacy for existing drugs used in the clinical setting has been discovered, and drug repositioning has been proposed as a strategy for developing those drugs as therapeutic agents for different diseases. This review describes a large-scale database study carried out following a discovery strategy for drug repositioning with the objective of improving survival rates after cardiopulmonary arrest and discusses future repositioning prospects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:137 |
|---|---|
| Enthalten in: |
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan - 137(2017), 12 vom: 10., Seite 1439-1442 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Zamami, Yoshito [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiopulmonary arrest |
|---|
| Anmerkungen: |
Date Completed 12.01.2018 Date Revised 12.01.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1248/yakushi.17-00139-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM278646727 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM278646727 | ||
| 003 | DE-627 | ||
| 005 | 20231225021105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.1248/yakushi.17-00139-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0928.xml |
| 035 | |a (DE-627)NLM278646727 | ||
| 035 | |a (NLM)29199254 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Zamami, Yoshito |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug Repositioning Research Utilizing a Large-scale Medical Claims Database to Improve Survival Rates after Cardiopulmonary Arrest |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2018 | ||
| 500 | |a Date Revised 12.01.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Approximately 100000 people suffer cardiopulmonary arrest in Japan every year, and the aging of society means that this number is expected to increase. Worldwide, approximately 100 million develop cardiac arrest annually, making it an international issue. Although survival has improved thanks to advances in cardiopulmonary resuscitation, there is a high rate of postresuscitation encephalopathy after the return of spontaneous circulation, and the proportion of patients who can return to normal life is extremely low. Treatment for postresuscitation encephalopathy is long term, and if sequelae persist then nursing care is required, causing immeasurable economic burdens as a result of ballooning medical costs. As at present there is no drug treatment to improve postresuscitation encephalopathy as a complication of cardiopulmonary arrest, the development of novel drug treatments is desirable. In recent years, new efficacy for existing drugs used in the clinical setting has been discovered, and drug repositioning has been proposed as a strategy for developing those drugs as therapeutic agents for different diseases. This review describes a large-scale database study carried out following a discovery strategy for drug repositioning with the objective of improving survival rates after cardiopulmonary arrest and discusses future repositioning prospects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cardiopulmonary arrest | |
| 650 | 4 | |a drug repositioning | |
| 650 | 4 | |a medical claims database | |
| 700 | 1 | |a Niimura, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takechi, Kenshi |e verfasserin |4 aut | |
| 700 | 1 | |a Imanishi, Masaki |e verfasserin |4 aut | |
| 700 | 1 | |a Koyama, Toshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ishizawa, Keisuke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan |d 1961 |g 137(2017), 12 vom: 10., Seite 1439-1442 |w (DE-627)NLM000042153 |x 1347-5231 |7 nnns |
| 773 | 1 | 8 | |g volume:137 |g year:2017 |g number:12 |g day:10 |g pages:1439-1442 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1248/yakushi.17-00139-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 137 |j 2017 |e 12 |b 10 |h 1439-1442 | ||